Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed
Executive Summary
Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.
You may also be interested in...
Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question
Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.
Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question
Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.
Roche's Diagnostic Foothold Gives Genentech A Leg Up In Oncology
Research to be presented at American Society of Clinical Oncology meeting shows role of biomarkers for lead compounds, including vemurafenib, MetMAb and Tarceva.